SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
Published: 31 August 2022
15 minPart 5 Q&A and Discussion
15 minPart 1 SGLT2 Inhibitors: Light at the End of the Tunnel Scott Solomon, John JV McMurray, Carolyn Lam, Muthiah Vaduganathan
10 minPart 2 SGLT2 Inhibitors Across the Spectrum of Heart Failure John JV McMurray
During this unique broadcast, ‘SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure’, Radcliffe Medical Education brings together a globally-renowned faculty to participate in a discussion centred around the presentation of the latest SGLT-2 inhibition data and how this translates to the treatment of Heart Failure patients.
Presented, and recorded, at ESC Congress 2022 in Barcelona, this programme is now available to watch on-demand. The programme is chaired by Prof Scott Solomon (Boston, US), who is joined by Prof John McMurray (Glasgow, UK), Prof Carolyn Lam (Singapore, SG) and Dr Muthiah Vaduganathan (Boston, US) while they explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
This satellite symposium is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the creation of the content.
Upon participation in this programme, physicians will be able to:
- Recall the results of key trials in HFmrEF in different patients' sub-groups
- Describe how SGLT-2 inhibitors can be used across the range of LVEF
- Apply emerging diagnostic approaches for HFpEF and HFmrEF
- Implement best-practice strategies across the range of LVEF
This programme is intended to educate:
- Global cardiologists
- Heart Failure specialists
- Primary care physicians
More from this programme
SGLT2 Inhibitors - Another piece of the Puzzle in Heart Failure
SGLT2 Inhibitors Across the Spectrum of Heart Failure
Practical Considerations for Treating HF With Mildly Reduced and Preserved EP
Implementing Best Practices Across the Spectrum of Heart Failure
Q&A and Discussion
Professor and Senior Consultant
Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore. Prof Lam is a world-renowned specialist in heart failure (particularly heart failure with preserved ejection fraction [HFpEF]). Her work in the PARAGON-HF and EMPEROR-Preserved trials led to the first FDA-approved treatment for HFpEF and the first robustly positive clinical outcomes trial in HFpEF to-date.